Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Barrett-Lee

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
British Journal of Cancer|May 5, 2005
Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administrationA Wardley, N Davidson, P Barrett-Lee, et al.
Cancer Chemotherapy and Pharmacology|September 30, 2006
TEXAS (Taxotere EXperience with Anthracyclines Study) trial: mature results of activity/toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBCK Malinovszky, S Johnston, P Barrett-Lee, et al.
Nature Genetics|October 1, 1992
A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndromeR Wooster, J Mangion, R Eeles, et al.
Journal of Genetic Counseling|July 5, 2015
Genetic Testing Considerations in Breast Cancer PatientsL France, J Gray, G Elwyn, et al.
Breast Cancer Research and Treatment|February 13, 2014
Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancerS Irshad, C Gillett, S E Pinder, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2015
Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trialM Jamal-Hanjani, R A'Hern, N J Birkbak, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2011
The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognosesH E Campbell, D Epstein, D Bloomfield, et al.
Endocrine-Related Cancer|August 23, 2005
Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatmentJ M W Gee, A Howell, W J Gullick, et al.
British Journal of Cancer|March 2, 2013
Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based studyS Walters, C Maringe, J Butler, et al.
Journal of Bone Oncology|December 29, 2018
Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)R E Coleman, M Collinson, W Gregory, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
British Journal of Cancer|May 5, 2005
Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administrationA Wardley, N Davidson, P Barrett-Lee, et al.
Cancer Chemotherapy and Pharmacology|September 30, 2006
TEXAS (Taxotere EXperience with Anthracyclines Study) trial: mature results of activity/toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBCK Malinovszky, S Johnston, P Barrett-Lee, et al.
Nature Genetics|October 1, 1992
A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndromeR Wooster, J Mangion, R Eeles, et al.
Journal of Genetic Counseling|July 5, 2015
Genetic Testing Considerations in Breast Cancer PatientsL France, J Gray, G Elwyn, et al.
Breast Cancer Research and Treatment|February 13, 2014
Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancerS Irshad, C Gillett, S E Pinder, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2015
Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trialM Jamal-Hanjani, R A'Hern, N J Birkbak, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2011
The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognosesH E Campbell, D Epstein, D Bloomfield, et al.
Endocrine-Related Cancer|August 23, 2005
Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatmentJ M W Gee, A Howell, W J Gullick, et al.
British Journal of Cancer|March 2, 2013
Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based studyS Walters, C Maringe, J Butler, et al.
Journal of Bone Oncology|December 29, 2018
Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)R E Coleman, M Collinson, W Gregory, et al.
Pageof 3